Alimera Sciences' Iluvien Data Presented at ARVO

Source: Alimera Sciences

Friday, May 06, 2016 | Conferences , Retina , Alimera Sciences


Alimera Sciences announced that data from seven Iluvien post marketing studies were presented during the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle.

The seven Alimera data presentations at ARVO were as follows:

·       Clinical Effectiveness of the Fluocinolone Acetonide Implant in Diabetic Macular Oedema Resistant to Anti-VEGF Therapy, authored by Spyridon Chalkiadakis, Fiona Harris and Simon Taylor, University of Surrey, and Royal Surrey County Hospital, Guildford, U.K.
 
·       Short-term Results of Fluocinolone Acetonide Intravitreal Implant (Iluvien) for Diabetic Macular Edema in Highly Treated Eyes, authored by Nisha Dhawlikar, Sumit P. Shah , David L. Yarian, Jonathan L. Prenner, Eric S. Friedman, Howard F. Fine, H. M. Wheatley, and Daniel B. Roth, Rutgers - Robert Wood Johnson Medical School, New Brunswick, New Jersey, and N.J. Retina, New Brunswick, New Jersey.


·       Preliminary Results from the RESPOND Trial:  Investigator-driven Study in Portugal to Evaluate Real-life Safety and Efficacy of Iluvien in Patients with Chronic DME, authored by Joao Figueira, Miguel Amaro, José Henriques and Vitor Rosas, CEC, AIBILI, Coimbra, Portugal, Coimbra University Hospital, Coimbra, Portugal, Hosptial Vila Franca de Xira, Vila Franca de Xira, Portugal, Instituto de Retina e Diabetes Ocular de Lisboa, Lisboa Portugal, Centro Hospitalar de São João, Porto, Portugal.
 
 
·       Change in Retinal Function and Morphology in Patients with Diabetic Macular Edema Switching from Anti-VEGF to Steroid (Fluocinolone Acetonide), authored by Radha Das and Usha Chakravarthy, School of Medicine, Queens University, Belfast, U.K.
 
·       A Retrospective Evaluation of the Efficacy and Safety of Fluocinolone Acetonide 0.2 Microgram Implant in Patients with Chronic Diabetic Macular Edema with Insufficient Response to Other Therapies, authored by Angelina Meireles, João Coelho, and Bernardete Pessoa, Centro Hospitalar do Porto-HSA, Porto, Portugal, and Medicine Faculty, Abel Salazar Biomedical Sciences Institute, Porto, Portugal.
 
·       The Outcome of Chronic Diabetic Macular Oedema in Patients Treated with Intravitreal Fluocinolone Acetonide (Iluvien), authored by Ibraheem El-Ghrably, James Cook University Hospital, Newcastle Upon-Tyne, U.K.
 
·        Sustained Intraocular Delivery of Fluocinolone Acetonide Slows Progression of Diabetic Retinopathy, authored by Peter A. Campochiaro, Johns Hopkins Wilmer Eye Institute, Baltimore, Maryland, Charles C. Wykoff, Retina Consultants of Houston, Houston, Texas, and Barry Kapik and Ken E. Green, Alimera Sciences, Inc.


Comments

You must be logged in to leave a comment.